CD33-Deficient Hematopoietic Cells for AML Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CD33-targeted therapies for acute myeloid leukemia (AML) face limitations due to 'on-target, off-leukemia' cytotoxicity, which depletes normal healthy myeloid lineage cells expressing CD33, leading to hematopoietic system depletion and suboptimal therapeutic outcomes.
Innovation Solution
Administering genetically engineered hematopoietic cells with reduced or eliminated CD33 expression, in conjunction with a cytotoxic agent like gemtuzumab ozogamicin, to protect normal myeloid cells from CD33-targeted therapy, thereby enhancing the therapeutic index and improving patient outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD33-targeted cytotoxic therapy is administered to treat AML, then leukemia cells are killed, but normal healthy myeloid lineage cells are depleted
Solution Approach 1:
The patent applies local quality by creating heterogeneous cell populations with different CD33 expression levels. Normal myeloid cells maintain wild-type CD33 expression and are protected through competitive interactions, while leukemia cells with altered CD33 expression (either overexpression or loss-of-function mutations) remain vulnerable to targeted therapy. This spatial and functional differentiation within the hematopoietic system allows selective elimination of malignant cells while preserving healthy tissue.
Solution Approach 2:
The patent exploits parameter changes in CD33 expression levels as a therapeutic strategy. By targeting cells with specific CD33 expression profiles (either overexpressing or null variants), the therapy selectively affects leukemia cells while normal cells with intermediate expression levels escape depletion. This parameter-based selection resolves the contradiction between killing leukemia and preserving normal hematopoietic cells.
2Productivity
If CD33-targeted therapy is used to eliminate leukemia cells, then tumor burden is reduced, but therapeutic index remains suboptimal due to off-target effects
Solution Approach 1:
The patent implements a feedback mechanism where normal myeloid cells with wild-type CD33 expression serve as a protective reservoir. These cells compete with leukemia cells for therapeutic targeting, creating a negative feedback loop that limits the intensity and duration of cytotoxic effects on normal tissue. The presence of these protected cells provides real-time feedback that modulates the overall therapeutic impact, improving the therapeutic index while maintaining leukemia clearance.
Data Source
AI summary
Aspects of the disclosure provide methods and compositions for treating a hematopoietic malignancy (e.g., acute myeloid leukemia). In some aspects, the disclosure provides methods of treatment using a population of genetically engineered CD33-deficient hematopoietic cells and a cytotoxic agent comprising an anti-CD33 antigen-binding domain.